Danimer Scientific, Inc.
DNMR · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.73 | 1.07 | 1.20 | 0.00 |
| FCF Yield | -0.84% | -0.79% | -0.34% | 0.37% |
| EV / EBITDA | -136.34 | -487.77 | -429.40 | -192.52 |
| Quality | ||||
| ROIC | -2.98% | -2.94% | -2.73% | -4.31% |
| Gross Margin | -84.76% | -90.50% | -85.04% | -78.50% |
| Cash Conversion Ratio | 0.66 | 0.84 | 0.48 | -0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.37% | -12.11% | -9.31% | -7.38% |
| Free Cash Flow Growth | 12.30% | -38.83% | -197.15% | 219.74% |
| Safety | ||||
| Net Debt / EBITDA | -20.77 | -61.61 | -32.11 | -14.87 |
| Interest Coverage | 0.00 | -2.13 | -2.10 | -3.65 |
| Efficiency | ||||
| Inventory Turnover | 0.61 | 0.55 | 0.73 | 0.77 |
| Cash Conversion Cycle | 290.80 | 315.24 | 245.50 | 247.31 |